Nanotechnology Now - Press Release: Arrowhead to Present at Upcoming Conferences

Home > Press > Arrowhead to Present at Upcoming Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead to Present at Upcoming Conferences

Pasadema. CA | Posted on November 11th, 2015

The Liver Meeting 2015®, 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) - San Francisco, November 13-17, 2015

November 15, 3:15 p.m. PST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver an oral presentation titled, "Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg"

November 16, 8:00 a.m. - 5:30 p.m. PST - Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and hepatology, The University of Hong Kong, and deputy chief of service, Queen Mary Hospital department of medicine, Hong Kong, will deliver a late-breaking poster presentation titled, "ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B"

November 16, 6:30 p.m. PST - Arrowhead management will host an Analyst and Investor Reception to discuss ARC-520 and key data being presented at the conference

November 17, 8:00 a.m. - 12:00 p.m. PST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver a poster presentation titled, "Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens"

Jefferies Autumn 2015 Global Healthcare Conference - London, UK, November 18-19, 2015

November 19, 2:40 p.m. GMT - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview

Piper Jaffray 27th Annual Healthcare Conference - New York, December 1-2, 2015

December 2, 3:00 p.m. EST - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray

HEP DART 2015 - Wailea, Hawaii, December 6-10, 2015

December 2, 6:40 p.m. HST - Bruce Given, M.D., Arrowhead chief operating officer, will deliver an oral presentation titled, "New insights on HBV biology from the ARC-520 development program"

December 8, 4:00 - 5:30 p.m. HST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver a poster presentation titled, "Sustained reduction in HBsAg, HBV DNA and HBeAg seroconversion in a chronically HBV-infected chimpanzee treated with nucleoside analog/ARC-520 combination therapy"

Links to the webcasts and copies of presentation materials, if available, can be accessed by visiting the Events section of the company's website at http://ir.arrowheadresearch.com/events.cfm.

About ARC-520

Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. Arrowhead is conducting Phase 2b multiple dose and combination studies in chronic HBV patients. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, and ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit ir.arrowheadresearch.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation.

For more information, please click here

Contacts:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400

or
Investor Relations:
The Trout Group
Chad Rubin
646-378-2947

or
Media:
Russo Partners
Matt Middleman, M.D.
212-845-4272